WALTHAM, Mass.--(BUSINESS WIRE)--Proteon Therapeutics, Inc., a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases, today announced that its lead product, PRT-201, has received orphan drug designation in the European Union (EU) for the prevention of arteriovenous access dysfunction in hemodialysis patients. Proteon is investigating the use of PRT-201, a locally acting recombinant human elastase applied during surgical placement of a vascular access, to reduce vascular access failure. PRT-201 has previously received fast track and orphan drug designations from the U.S. Food and Drug Administration (FDA).
Help employers find you! Check out all the jobs and post your resume.
